Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
NTH 0.160 −3.0% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.70 −4.8% IVN 10.64 −1.3% MASS 0.090 +0.0% LIF 26.72 −1.8% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.280 −3.5% ODV 3.37 +0.0% MINK 0.105 +0.0% ZEN 0.680 +6.2% LCE 0.250 +4.2% CBA 0.060 −29.4% NTH 0.160 −3.0% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.70 −4.8% IVN 10.64 −1.3% MASS 0.090 +0.0% LIF 26.72 −1.8% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.280 −3.5% ODV 3.37 +0.0% MINK 0.105 +0.0% ZEN 0.680 +6.2% LCE 0.250 +4.2% CBA 0.060 −29.4%
Other

TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications

By The Northwire Desk — AI Analysis Jan 23, 2026 · 16:06 VIVI · 1 TempraMed Technologies Ltd.
VIVI · Price

Executive Summary

  • TempraMed Technologies announced the commercial launch of VIVI Med™, a new temperature‑protection solution for medication vials, biologics, GLP‑1 therapies, and other temperature‑sensitive injectables.
  • The addition expands TempraMed’s addressable market by targeting high‑cost biologics, specialty pharmacies, healthcare providers, and B2B partners, reducing reliance on insulin‑pen formats.
  • VIVI Med™ leverages the company’s patented, passive thermal‑insulation technology to provide 24/7/365 protection without batteries or external power, opening new revenue streams across consumer, institutional, and global distribution channels.

Key Details

  • Product Portfolio Expansion: TempraMed now offers four product lines – VIVI Cap™ / VIVI Cap Smart™, VIVI Epi™, VIVI Med™, and a forthcoming smart platform.
  • Targeted Medication Categories:
  • Biologics (e.g., Humira®)
  • GLP‑1 receptor agonists
  • Insulin vials & other injectable medication vials
  • Temperature‑sensitive glucose test strips
  • Alternative epinephrine auto‑injectors
  • Key Features of VIVI Med™:
  • Passive thermal protection (no refrigeration, batteries, or charging) for years of use.
  • Compact, lightweight, reusable design suitable for travel and active lifestyles.
  • Constructed from space‑grade materials for durability and long life.
  • Strategic Commercial Impact:
  • Enables pursuit of larger, diversified revenue opportunities: high‑cost biologics patients, specialty pharmacies, healthcare providers, institutional B2B partners.
  • Anticipated to strengthen long‑term growth profile by broadening product breadth and supporting future reimbursement, enterprise, and global distribution initiatives.
  • Management Commentary: CEO Ron Nagar highlighted that VIVI Med™ “materially expands our addressable market” and creates new opportunities across consumer, B2B, and healthcare‑system channels.

Notable Quotes

“VIVI Med™ is a strategic expansion of our platform that allows us to address a much broader universe of temperature‑sensitive medications… This product materially expands our addressable market and creates new opportunities across consumer, B2B, and healthcare‑system channels.” – Ron Nagar, CEO, TempraMed Technologies Ltd.

Read the original news release →

More from TempraMed Technologies Ltd.

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property